Imperial College London
Alternate

Emeritus ProfessorGavinDonaldson

Faculty of Medicine, National Heart & Lung Institute

Emeritus Professor of Respiratory Studies
 
 
 
//

Contact

 

+44 (0)20 7594 7859gavin.donaldson

 
 
//

Location

 

B141Guy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Nici:2020:10.1164/rccm.202003-0625ST,
author = {Nici, L and Mammen, MJ and Charbek, E and Alexander, PE and Au, DH and Boyd, CM and Criner, GJ and Donaldson, GC and Dreher, M and Fan, VS and Gershon, AS and Han, MK and Krishnan, JA and Martinez, FJ and Meek, PM and Morgan, M and Polkey, MI and Puhan, MA and Sadatsafavi, M and Sin, DD and Washko, GR and Wedzicha, JA and Aaron, SD and American, Thoracic Society Assembly on Clinical Problems},
doi = {10.1164/rccm.202003-0625ST},
journal = {American Journal of Respiratory and Critical Care Medicine},
pages = {1--14},
title = {Pharmacologic management of COPD: an official American Thoracic Society clinical practice guideline.},
url = {http://dx.doi.org/10.1164/rccm.202003-0625ST},
volume = {201},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: This document provides clinical recommendations for the pharmacologic treatment of COPD. It represents a collaborative effort on the part of a panel of expert COPD clinicians and researchers along with a team of methodologists under the guidance of the ATS. METHODS: Comprehensive evidence syntheses were performed on all relevant studies which addressed the clinical questions and critical patient-centered outcomes agreed upon by the panel of experts. The evidence was appraised, rated, and graded, and recommendations were formulated using GRADE. RESULTS: After weighing the quality of evidence and balancing the desirable and undesirable effects, the guideline panel made six recommendations, listed in full in the document. CONCLUSIONS: The task force made recommendations on the pharmacologic treatment of COPD based on currently available evidence. Additional research in populations that are under-represented in clinical trials is needed, including studies in COPD patients 80 years of age and older, those with multiple chronic health conditions, and those with a co-diagnosis of COPD and asthma.
AU  - Nici,L
AU  - Mammen,MJ
AU  - Charbek,E
AU  - Alexander,PE
AU  - Au,DH
AU  - Boyd,CM
AU  - Criner,GJ
AU  - Donaldson,GC
AU  - Dreher,M
AU  - Fan,VS
AU  - Gershon,AS
AU  - Han,MK
AU  - Krishnan,JA
AU  - Martinez,FJ
AU  - Meek,PM
AU  - Morgan,M
AU  - Polkey,MI
AU  - Puhan,MA
AU  - Sadatsafavi,M
AU  - Sin,DD
AU  - Washko,GR
AU  - Wedzicha,JA
AU  - Aaron,SD
AU  - American,Thoracic Society Assembly on Clinical Problems
DO  - 10.1164/rccm.202003-0625ST
EP  - 14
PY  - 2020///
SN  - 1073-449X
SP  - 1
TI  - Pharmacologic management of COPD: an official American Thoracic Society clinical practice guideline.
T2  - American Journal of Respiratory and Critical Care Medicine
UR  - http://dx.doi.org/10.1164/rccm.202003-0625ST
UR  - https://www.ncbi.nlm.nih.gov/pubmed/32283960
UR  - https://www.atsjournals.org/doi/10.1164/rccm.202003-0625ST
VL  - 201
ER  -
Download